Skip to content

Celcuity CELC Depreciation

Depreciation at other companies

Gilead Sciences logo
Gilead SciencesGILD
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
Tango Therapeutics logo
Tango TherapeuticsTNGX
Medpace Holdings, Inc. logo
Medpace Holdings, Inc.MEDP

Other financials

Income statement

See full
Operating income-$50.5M-39.8%
Net income-$52.8M-42.8%
EPS (diluted)-$0.97-12.8%

Balance sheet

See full
Cash & equivalents$145.2M+781%
Total debt$137.9M+30.7%
Total equity$53.5M-38.2%
Total assets$410.2M+88.0%

Cash flow

See full
Operating cash flow-$55.1M-53.6%
CapEx$249.0K+315%
Free cash flow-$55.3M-54.0%

Valuation

See full
Market cap$4.28B+1,370%
Enterprise value$4.27B+1,086%

Returns & leverage

See full
Return on equity-275.2%-990pp
Debt / equity2.6×+1.4×
Current ratio12.3×+5.7×

Where this comes from

Reported directly by Celcuity in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: Celcuity’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Celcuity's depreciation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Celcuity's depreciation?
Celcuity (CELC) reported depreciation of $47K in Q1 2026.
How has Celcuity's depreciation changed year-over-year?
Celcuity's depreciation increased by 27.0% year-over-year, from $37K to $47K.
What is the long-term trend for Celcuity's depreciation?
Over 4 years (2021 to 2025), Celcuity's depreciation has grown at a -13.9% compound annual growth rate (CAGR), from $303.24K to $167K.